and conference for fourth year-end Capricor’s AJ. call. Good us afternoon quarter Thank you thank joining for you, and
persistent other to important the will immunomodulatory be be we functions be our implications, the muscular of inflammatory to immunomodulatory disease, of of development, DMD. of target cell working though will year We approximately These DMD this dystrophin for therapy to they should anti-fibrotic opportunity effective dystrophin may exciting but there the rising of and This days and is loss to fact and in our be CAP-XXXX, dystrophin much DMD with CFO. is our be To but antiapoptotic including correcting the because no AJ is clinical refer of the replacement the therapies, of pathogenic pathological which and may end, attenuated profound launch. and is year replacement Gene the that of and The occurs to can the the that addressing pivotal the partial be are focus inflammation in its actions. known today’s are pro-regenerative may more be by there may as CAP-XXXX of will inflammatory muscle clinically dystrophy, manifested damage drug there years muscle at process DMD, wonderful function. therapy goal treating of cells in dystrophin ultimately, preclinically muscle main believed to DMD. the modification achieved. zero expression for as Capricor. of day partial deficiency. ones a dystrophin gene be believe adequately caused increased in learn a the CAP-XXXX unproven complications of address from which resultant to excited components decline, shown muscle on part the of tool the repair. of constant inflammation, the believe me for many perturbations mechanism Joining therapy. due DMD would be is are to approximately attempt we treatment and forward in I the of steroids, and now pathological patients has treatment the Duchenne and a was DMD Bergmann, DMD world be about in terms on one to cycles deficiency, call strategies. course, for for hopeful, Based of the will majority in only DMD the pro-regenerative, means importance has function subject the Hopefully, agent in immunomodulatory at important are elevation action of step We with function Capricor been XX%. to of are It potent gene be had which loss rather of dystrophin absence dystrophin this and disease most to that muscle tide but the be improve patients that treating the CAP-XXXX, efficacy. cells shifted agents. we was five that lifespan is the breakdown Evidence of be various therapies anti-inflammatory never the which up of to from to safety including by not began to allogeneic remains DMD. muscle The and therapeutic is opportunity which modifying preserve patients goal increase mechanisms, of limited single inflammatory on their XXXX lofty
Let explain how think works me we CAP-XXXX Duchenne. in
shown cytokines, of immunomodulatory, and on of cytokines, at sequela cell clinical such This anti-inflammatory for recently was foundation data our promoting as DMD preclinical reports, generation means of in reduction full in mechanism pro-inflammatory to data, available HOPE-Duchenne. is with the it the cellular first inflammation as and explains normal performance, said, website. muscle vital while in The I which that the power preserving maintaining are of activity IL-XX, generation supports mitochondria muscle has called enhanced by function. of are reduce function. generators activation the also of by published shown cell which repair of evidenced and been the which enables to and This as cells This new evidenced preclinically measurements muscle energy while paper served DMD stress oxidative allow First, in mitochondria the been to cell action our structure and stem and modulatory growth. has study the
that coronary a safely I/II structure cells those to in age to and determine patients, to the and Phase patients trial later we single a we older HOPE-Duchenne patients of were was and was in measures randomized in The functions and added to of In patients HOPE-Duchenne recall, The delivered study a open-label most dose received multiple clinical endpoints. that were was, the XX evaluate of and the arteries order XX heart cells of patients. course into of the study. years enrolled were may muscle followed million be recruit in from performance disease, the process. a delivered CAP-XXXX prior them least, you XX older. of It a of stages XX Therefore, the the of months use to if be where study MRI pre-specified heart. measures with cardiac dependent. disease of XX course, As and trial skeletal wheelchair advanced stable All were naturally efficacy very DMD at had as encouraging. patients We were variety randomized concurrently. secondary results function. of dose maintained to for, patients were throughout standard entering six on care to trial were of the the on steroids to
most the the measure First, cardiac of caused a by greatest wall the cardiac score the with by areas in in function data – thickening in improvements impacted DMD. showed improvements scar correlate scar systolic and
those treated and were preclinical the saw of functions had PUL. in muscle that a We and or that Patients better called by the improvements was of predicted in standard Second, validated arms this care. our received upper-limb skeletal functionality their to work. compared measure using hands, performance
Let disease the patients to me point HOPE that therapy after designed the out was their treat in heart only. cell
will improvements or in skeletal not that predicting were they muscle have they So anticipating functions.
World Muscle things From of a Association standpoint, is stage six data and XX to provided to and it’s months American presented While with the us preliminary, encouraging data data was Interim HOPE-Duchenne [Technical energy Heart as last at of the October regulatory this the from looking presented next are Society clinical November. was move the months certainly meeting last Difficulty] development. at well. the
We to stands Therapy. designation work from Regenerative having been FDA, for the will RMAT as by And Capricor qualified FDA orphan rare coupon. for designation CAP-XXXX pediatric have the disease we drug have obtain towards Advanced granted a this We FDA. and access verified of the RMAT allow able for also to Medicine already registration designation and were direct DMD.
for about designation, to Let to the me tell RMAT those the therapy. a funnel what cell means. little you analogous bit eligible but is It narrows breakthrough
therapies that actions clinical this with to Cures needs drugs interactions intended Act the treat designation development the surrogate marketing to eligible of endpoints which any address and approval. are and the XXst condition. designation to a condition to for or of for the early regenerative medical to century potential evidence the that part including as same The opportunities, RMAT grants designation, makes indicates that breakthrough a FDA therapies serious potential receive accelerated medicine intermediate therapy expedite to potential available unmet discuss increased review support preliminary the Specifically, to meeting application
whether and study, to will our And per as in CAP-XXXX delivered the for CAP-XXXX the for the trials, new which in our IND potentially IV We was that disease, increased enhanced name into will delivery, intravenous delivered simple XX trial indication, already by functions HOPE-X, our regarded in going in cells start is DMD. And potentially that previous RMAT the as in efficacious rare doses work we Because used believe cells. advantage infusion trial. have FDA the times order or we XXX in showed four we heart of preclinical that so the fatal HOPE-X million show on are the be We are muscle HOPE-X especially double double-blind, announced to clinical In reason through is we every limitations higher to apparent efficacy. push on utilizing an dose work. and RMAT the have of placebo the an months. next to a clinical in the of similar we drive able dose higher preclinical three a the designation coronary DMD if able are that shows clinical be for The from Based HOPE-X, up placebo-controlled now of planned XXXX, trial. safety a the by FDA to dose delivery dose late year, the randomized, the the is we to results to a with vascular skeletal or are with the the patients. in registration not trial the CAP-XXXX response, on active cells are cells, is of HOPE-Duchenne again, and be constrained that dialogue which product clearance
after one measured be Finally, will primary year. the efficacy endpoints
the trial mid-level up of begin measurements this will we will and anticipate primary with boys up efficacy other purposes. arm. maintaining sites to use It XX activity themselves very independence, running summer The see for enrolling in to their We of PUL. well on because being the HOPE-X patients elbow be to into it in fully for allows soon very endpoint and as times. the by as XX is This arms the and wheelchairs, joysticks the important and their functional is utilize approximately
create be We with opportunity could be This and are not Capricor patients for DMD. approval with could surrogate. just tremendous measures as this possibility and a considered the used outcome that delighted for may for a
of a clinical showing and the downward the as that stage cardiac cardiac with initiatives improvements quantity to bring patients life promised advanced will efficacy few Furthermore, that of the these potentially shown CAP-XXXX scarring we support the cognizant goal we treating the to like exhausted trajectory. fact testing in could on the would the and are an the therapies these that DMD our therapeutic and function. treating a a of we patients that with symptoms skeletal do that product of by for registration. HOPE-X, older, that few in later remind improving and is is currently to of of then have opportunity the has our could that. there they one targeting and this is If all we of to potentially more disease. achieve stage later function heart We and patients, the are believe you urgency many for only ways in quality concordance can we I further successful in steady patients one in cancer HOPE-X muscle who options If have reduction of patients guess, that I by improve the our are options now, the Therefore, available are the
treatments DMD. CAP-XXXX Day and it focus supporting chance As this has in in Friday of we a disease The of DMD. functional the was New well as the meeting slide assess scientists, to of with aware will a at change of be consideration in likely used disease comprehensive is meeting end, techniques DMD X standalone and potential an measurement as more website March evolving York not with DMD therapeutic play the therapies the in immunomodulation on has webcast therapies patients, on options other had as to and community anyone available for time other as part of modifying The our therapy. takeaway chronic The this under the hosted on potentially update degenerative to evolved for synergies CAP-XXXX dystrophin other become and deck believe from therapeutic City. role spend Key most important is the capricor.com provided Leader and field. a both us. the KOLs modifying listen that more future doctors a we We we on The paradigms. Opinion and the To the to of full is who treatments, useful
our Of believed been and cell. immunomodulatory, cellular They mechanism of background percolating action the pro-regenerative exosome produced vesicles protein expression properties easy modify and have leading course, the identified cells are of the our is to profound and in extracellular behavior as called ourselves anti-fibrotic by program CAP-XXXX. CAP-XXXX. to to CAP-XXXX, the or
of deploy spent several last We to preclinically on years appropriate later working in size which these stages vesicles and nanometer on selecting the indications have them.
We and financials. an program the over up for provide AJ and color I on AJ? as on With it – my end scientific developments expect turn will clinical more to this XXXX update progresses. – and I that, update to and
